

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 February 2011 (03.02.2011)

PCT

(10) International Publication Number  
**WO 2011/014255 A8**

- (51) **International Patent Classification:**  
*A01N 43/42* (2006.01) *A61K 31/42* (2006.01)
- (21) **International Application Number:**  
PCT/US2010/002129
- (22) **International Filing Date:**  
29 July 2010 (29.07.2010)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/273,167 30 July 2009 (30.07.2009) US
- (71) **Applicant (for all designated States except BB, US):** TEVA PHARMACEUTICAL INDUSTRIES LTD. [IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petach-Tikva (IL).
- (71) **Applicant (for BB only):** TEVA PHARMACEUTICALS USA, INC. [US/US]; 1090 Horsham Road, North Wales, PA 19454 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** TARCIC, Nora [IL/IL]; Migdal David 29/1, Modiin (IL). HAVIV, Asi [IL/IL]; 76802 Kvutsat Shiller (Gan Shlomo) (IL). BLAUGRUND, Eran [IL/IL]; 94 Remez Street, 76449 Rehovot (IL). KAYE, Joel [IL/IL]; 14/5 Hazamir Street, 42752 Netanya (IL).
- (74) **Agent:** WHITE, John, P.; Cooper & Dunham LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report (Art. 21(3))
- (48) **Date of publication of this corrected version:**  
15 March 2012
- (15) **Information about Correction:**  
see Notice of 15 March 2012

(54) **Title:** TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD

(57) **Abstract:** This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.



WO 2011/014255 A8